We believe that we are currently the market leader in the surgical treatment of Afib. At age 40, remaining lifetime risk for Afib is 26% for men and 23% for women. The cryoICE devices enables the user to make linear ablations of varied lengths. Products for appendage management:AtriClip System. Often, Afib procedures are performed concomitantly with other cardiac treatments. The ablations are made from the inside of the heart using a flexible catheter. Provide Training and Education. Enrollment began in 2014 and was completed in August 2018. In January 2020, we received approval for a CAP for the aMAZE IDE trial. Clinical trials are subject to extensive recordkeeping and reporting requirements. Pervasive and Continuing Regulation. At AtriCure, the employee experience is crucial to the ongoing success of the company. Throughout the COVID-19 pandemic, our employees have been our first and foremost focus. FDA does not regulate the practice of medicine. Even in the absence of a claim, our insurance rates may rise in the future. Any of these events could negatively affect our financial condition. We cannot assure you that one or more of these factors will not harm our business. The global nature of our business increases our tax risks. Our historical write-offs of accounts receivable have not been significant. This may have a negative impact on the market price of our common stock. We do not anticipate paying cash dividends on our common stock in the foreseeable future.